Wallaby Medical Acquires German Neurovascular Leader phenox (including femtos)
April 21, 2022
Wallaby Medical acquired phenox GmbH (including femtos GmbH) from investors including SHS and NRW Bank in a transaction announced April 21, 2022, for approximately EUR 500 million including milestone payments. The deal combines Wallaby's and phenox's complementary neurovascular product portfolios and manufacturing capabilities to accelerate geographic expansion and broaden R&D and commercial reach across the U.S., Europe, China and Japan.
- Buyers
- Wallaby Medical
- Targets
- phenox GmbH, femtos GmbH
- Sellers
- SHS Gesellschaft für Beteiligungsmanagement mbH, NRW Bank
- Industry
- Medical Devices
- Location
- North Rhine-Westphalia, Germany
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Axol Bioscience Acquires Newcells Biotech's Ophthalmology Business
February 23, 2026
Biotechnology
Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.
-
Boston Scientific Acquires Axonics, Inc.
November 15, 2024
Medical Devices
Boston Scientific agreed to acquire Axonics, a medical technology company focused on urinary and bowel dysfunction, for $71 per share in cash, valuing the equity at approximately $3.7 billion. The boards approved the transaction, which was expected to close in the first half of 2024, and Boston Scientific later announced the acquisition closed on November 15, 2024.
-
Axol Bioscience Acquires Phenocell
October 21, 2024
Biotechnology
Axol Bioscience Ltd. has fully acquired Phenocell SAS, adding Phenocell’s iPSC-derived skin and retinal cell lines and custom bioassay services to Axol’s drug discovery product portfolio. The acquisition expands Axol’s capabilities into ophthalmology and dermatology (including AMD and cosmetics testing); financial terms were not disclosed.
-
Novartis to Acquire MorphoSys in $2.9 Billion Deal
February 7, 2024
Pharmaceuticals
Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).
-
Kymanox Acquires anteris medical GmbH and anteris helvetia AG
February 2, 2023
Professional Services
Kymanox Corporation has acquired anteris medical GmbH (Germany) and anteris helvetia AG (Switzerland) to expand its European footprint and broaden its life-science professional services capabilities. The deal brings additional regulatory, quality, and combination-product expertise to Kymanox; terms were not disclosed.
-
Kymanox Acquires Neuma LLC
August 9, 2021
Medical Devices
Kymanox Corporation, a life-sciences-focused professional services firm, has acquired Neuma LLC, an engineering services provider specializing in drug delivery devices and combination products. The deal — funded by a recent growth recapitalization from WestView Capital Partners — expands Kymanox's product development and combination-product capabilities to better support clients across biopharma and medical device markets.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.